Dinakar Sasmal

Learn More
Recently glutamate transporters have emerged as a potential therapeutic target in a wide range of acute and chronic neurological disorders, owing to their novel mode of action. The modulation of GLT-1, a major glutamate transporter has been shown to exert neuroprotection in various models of ischemic injury and motoneuron degeneration. Therefore, an attempt(More)
Glutamate transport represents a key mechanism for maintaining low level of glutamate in the extracellular milieu to restrict the excitotoxic action of glutamate released during ischemia/reperfusion (I/R) injury. Recently, it has been reported that glutamate transporter-1 (GLT-1) is a novel target for peroxisome proliferator-activated receptor-γ (PPARγ)(More)
We explored the attenuating effects of NP-9 on β-amyloid (Aβ) aggregation and amyloid-induced toxicity. NP-9 is a recently reported monoamine oxidase B (MAO-B), and acetylcholinesterase (AChE) inhibitor. In the present study, we found that NP-9 inhibited AChE activity in a dose-dependent manner with a maximal inhibition dose of 8 mg/kg, i.p. It inhibited Aβ(More)
The present study was designed to estimate the detailed antidiabetic activity of Pterospermum acerifolium (L.) Willd flowers. In vitro alpha amylase inhibition study was carried out on 50% ethanol extract of flowers (PAFEE) and its various fractions. The active ethyl acetate fraction (PAFEF) was subfractionated into three subfractions (PAFE1, PAFE2, and(More)
Deltamethrin (DLM), a type 2 synthetic pyrethroid insecticide, is widely used in home and agricultural pest control. Humans are exposed to DLM by various modes like air, water, vegetables, etc. at low concentrations. DLM has been considered as safe for humans at low concentrations. At present, its exposure has been increased due to restriction on the sale(More)
Monoamine oxidase (MAO) B is a validated target for many neurodegenerative diseases. Recently we have reported a few pyrazolines as reversible and selective MAO-B inhibitors. Amongst them, we have selected the most potent analog, NP-9 (Ki=0.31 nM; selectivity index, MAO-B/A more than 100) for the current preclinical study. It selectively inhibited MAO-B(More)
Cimetidine is the prototype antiulcer drug having the imidazole nucleus and acts by blocking histamine H 2 receptors. Keeping this context in mind, an attempt has been made to study the antihistaminic activity of some novel 1-substituted imidazole derivatives on isolated guinea pig atria to reveal their desired pharmacological effects. In the present(More)
  • 1